Casdin Capital, LLC
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | $482.7M | 2,577,333 | +5.18pp | 26q | HELD | |
| RELAY THERAPEUTICS INC | RLAY | $300.0M | 16,035,240 | +4.15pp | 24q | +11.2%+$30.2M | |
| GENEDX HOLDINGS CORP | WGS | $254.5M | 3,707,164 | -1.88pp | 13q | +23.3%+$48.1M | |
| BIOLIFE SOLUTIONS INC | BLFS | $131.5M | 4,655,000 | -2.03pp | 31q | -21.9%-$36.8M | |
| ILLUMINA INC | ILMN | $93.2M | 530,000 | -0.28pp | 16q | HELD | |
| STANDARD BIOTOOLS INC | LAB | $73.0M | 88,783,856 | -2.52pp | 13q | HELD | |
| STRUCTURE THERAPEUTICS INC | GPCR | $63.1M | 1,175,000 | -1.13pp | 14q | HELD | |
| DENALI THERAPEUTICS INC | DNLI | $52.6M | 2,045,000 | -0.04pp | 31q | +11.1%+$5.3M | |
| NEUROGENE INC | NGNE | $48.6M | 1,545,361 | +0.26pp | 11q | +8.8%+$3.9M | |
| BEAM THERAPEUTICS INC | BEAM | $46.3M | 1,350,000 | -0.12pp | 23q | HELD | |
| 10X GENOMICS INC | TXG | $40.3M | 1,050,000 | -1.64pp | 3q | -53.8%-$47.0M | |
| SCHOLAR ROCK HLDG CORP | SRRK | $36.6M | 665,000 | +0.53pp | 3q | +90.0%+$17.3M | |
| PERSONALIS INC | PSNL | $34.2M | 2,550,000 | +0.94pp | 2q | +59.4%+$12.7M | |
| GRAIL INC | GRAL | $32.8M | 480,000 | +0.74pp | 2q | +108.7%+$17.1M | |
| GUARDANT HEALTH INC | GH | $27.8M | 185,000 | -0.81pp | 9q | -41.3%-$19.5M | |
| MAZE THERAPEUTICS INC | MAZE | $25.2M | 843,857 | -0.45pp | 6q | +11.2%+$2.5M | |
| HIMS & HERS HEALTH INC | HIMS | $24.3M | 700,000 | +0.11pp | 6q | HELD | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $22.6M | 75,000 | -0.75pp | 31q | HELD | |
| TAYSHA GENE THERAPIES INC | TSHA | $22.1M | 3,250,000 | +0.01pp | 3q | HELD | |
| AGOMAB THERAPEUTICS NV | AGMB | $20.1M | 1,550,000 | -0.22pp | 2q | HELD | |
| SEPTERNA INC | SEPN | $18.5M | 553,268 | -0.08pp | 7q | HELD | |
| PARABILIS MEDICINES INC | PBLS | $17.7M | 645,690 | - | new | NEW | |
| SIONNA THERAPEUTICS INC | SION | $17.6M | 400,000 | - | new | NEW | |
| VERACYTE INC | VCYT | $16.2M | 276,308 | +0.14pp | 10q | HELD | |
| ADLAI NORTYE LTD | ANL | $14.4M | 1,250,000 | +0.44pp | 2q | +132.1%+$8.2M | |
| PRIME MEDICINE INC | PRME | $11.7M | 3,167,175 | -0.25pp | 15q | HELD | |
| ABSCI CORPORATION | ABSI | $11.3M | 973,260 | +0.34pp | 20q | HELD | |
| QUEST DIAGNOSTICS INC | DGX | $10.6M | 50,000 | -0.21pp | 3q | HELD | |
| SAREPTA THERAPEUTICS INC | SRPT | $8.4M | 470,000 | - | new | NEW | |
| UNIQURE NV | QURE | $6.9M | 150,000 | - | new | NEW | |
| INTELLIA THERAPEUTICS INC | NTLA | $6.0M | 355,000 | -0.04pp | 2q | HELD | |
| MODERNA INC | MRNA | $5.3M | 75,000 | -0.03pp | 2q | HELD | |
| DISC MEDICINE INC | IRON | $4.8M | 65,000 | -0.08pp | 2q | HELD | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $4.5M | 186,014 | -0.01pp | 21q | HELD | |
| CENTURY THERAPEUTICS INC | IPSC | $3.0M | 1,228,190 | -0.06pp | 21q | HELD | |
| CONTINEUM THERAPEUTICS INC | CTNM | $2.4M | 148,333 | -0.03pp | 9q | HELD | |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | $2.2M | 282,312 | -0.08pp | 4q | HELD | |
| EDITAS MEDICINE INC | EDIT | $1.4M | 445,000 | - | new | NEW | |
| PACIFIC BIOSCIENCES CALIF IN | PACB | $1.2M | 723,767 | -0.01pp | 12q | HELD | |
| KARDIGAN INC | KARD | $1.2M | 50,000 | - | new | NEW | |
| RECURSION PHARMACEUTICALS IN | RXRX | $606.7K | 165,323 | -0.01pp | 7q | HELD | |
| GINKGO BIOWORKS HOLDINGS INC | DNA | $361.6K | 36,493 | flat | 8q | HELD | |
| TENAYA THERAPEUTICS INC | TNYA | $267.5K | 361,969 | -0.01pp | 20q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.4B | 72.4% |
| Healthcare Services | $400.3M | 20.0% |
| Medical Devices | $131.5M | 6.6% |
| Not classified | $18.9M | 0.9% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $2.0B | 43 | 6 | 9 | 3 | 3 | 77.4% | 45 |
| Q1 2026 | $1.3B | 40 | 9 | 7 | 4 | 7 | 77.3% | 45 |
| Q4 2025 | $1.6B | 38 | 7 | 9 | 4 | 1 | 79.5% | 48 |
| Q3 2025 | $1.2B | 32 | 5 | 4 | 6 | 6 | 84.5% | 45 |
| Q2 2025 | $1.1B | 33 | 1 | 9 | 12 | 12 | 85.3% | 45 |
| Q1 2025 | $1.2B | 44 | 8 | 5 | 9 | 2 | 79.8% | 45 |
| Q4 2024 | $1.5B | 38 | 5 | 3 | 5 | 2 | 78.8% | 45 |
| Q3 2024 | $1.5B | 35 | 1 | 10 | 6 | 4 | 78.3% | 45 |
| Q2 2024 | $1.3B | 38 | 4 | 7 | 4 | 2 | 77.0% | 110 |
| Q1 2024 | $1.3B | 36 | 3 | 12 | 4 | 3 | 71.6% | 45 |
| Q4 2023 | $1.0B | 36 | 2 | 7 | 8 | 4 | 71.8% | 45 |
| Q3 2023 | $903.5M | 38 | 2 | 7 | 11 | 5 | 70.2% | 45 |
| Q2 2023 | $1.1B | 41 | 6 | 7 | 9 | 5 | 63.1% | 45 |
| Q1 2023 | $1.2B | 40 | 2 | 10 | 10 | 6 | 64.8% | 45 |
| Q4 2022 | $1.3B | 44 | 11 | 10 | 7 | 3 | 64.8% | 45 |
| Q3 2022 | $1.5B | 36 | 6 | 11 | 8 | 10 | 75.7% | 45 |
| Q2 2022 | $1.2B | 40 | 5 | 2 | 19 | 12 | 68.0% | 46 |
| Q1 2022 | $2.2B | 47 | 2 | 1 | 7 | 8 | 55.2% | 46 |
| Q4 2021 | $3.5B | 53 | 5 | 5 | 12 | 6 | 53.0% | 45 |
| Q3 2021 | $4.0B | 54 | 8 | 9 | 5 | 8 | 52.6% | 46 |
| Q2 2021 | $3.9B | 54 | 11 | 8 | 3 | 5 | 57.2% | 47 |
| Q1 2021 | $3.4B | 48 | 4 | 15 | 6 | 7 | 63.1% | 47 |
| Q4 2020 | $3.4B | 51 | 11 | 11 | 3 | 5 | 62.2% | 47 |
| Q3 2020 | $2.2B | 45 | 6 | 13 | 3 | 3 | 63.1% | 47 |
| Q2 2020 | $1.7B | 42 | 7 | 11 | 10 | 3 | 59.6% | 45 |
| Q1 2020 | $942.0M | 38 | 7 | 12 | 8 | 1 | 58.1% | 45 |
| Q4 2019 | $1.1B | 32 | 2 | 10 | 8 | 3 | 62.3% | 45 |
| Q3 2019 | $966.3M | 33 | 2 | 11 | 6 | 0 | 64.3% | 95 |
| Q2 2019 | $1.1B | 31 | 5 | 13 | 3 | 3 | 64.7% | 44 |
| Q1 2019 | $910.4M | 29 | 2 | 9 | 4 | 4 | 64.4% | 45 |
| Q4 2018 | $584.5M | 31 | 0 | 0 | 0 | 0 | 58.4% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.